Connect with us

NEWS

A Shanghai Infusion Corrected 54 Percent of an Alpha-1 Liver

YolTech’s YOLT-202 corrected 54 percent of SERPINA1 alleles in a German PiZZ patient, the first published in vivo base-editing liver biopsy.

Published

on

A 66-year-old man with severe alpha-1 antitrypsin deficiency had 54 to 57 percent of his liver SERPINA1 alleles corrected after one 35 mg infusion of an in vivo base editor. The biopsy, taken 10 weeks later in a Shanghai trial of YolTech Therapeutics’ YOLT-202, is the first published tissue readout of in vivo base editing in a human liver.

Hannover Medical School framed the case as a German clinical win. The drug, the patents, and the infusion suite sit with a Shanghai company, and the patients had to fly because PiZZ disease is rare in Asia.

The First Published Biopsy of an Edited Human Liver

The published liver biopsy analysis appeared in the Journal of Hepatology on 1 November 2026. Simon Alexander Krooss and colleagues report a man with two copies of the Z mutation (Glu342Lys, also called E342K) in SERPINA1, treated inside the YOLT-202 investigator-initiated study (NCT07193615) at Renji Hospital.

Ten weeks after a single intravenous dose, the lowest planned at 35 mg, sequencing of the sampled liver found correction of the PiZZ variant in 54 percent of alleles by Sanger reads and 57 percent by Illumina reads. The assays found no bystander edits at the target site and no off-target signal in the sites they checked. Histology showed no hepatitis. Elastography before treatment had already put him at F2 fibrosis.

Circulating alpha-1 antitrypsin rose from 0.15 g/L before the infusion to 0.70 g/L at 10 weeks, above the protective threshold of 0.57 g/L (11 μM). The protein still blocked elastase. Liver enzymes ticked up after the dose, then returned to baseline by day 14.

THE PUBLISHED CASE AT A GLANCE

Measure Finding
Patient 66-year-old man, PiZZ
Dose 35 mg intravenous, lowest planned
Biopsy timing 10 weeks
Allele correction 54 percent Sanger; 57 percent Illumina
Serum AAT 0.15 g/L to 0.70 g/L
Protective threshold 0.57 g/L (11 μM)
Bystander and off-target None detected in the assays used
Pre-existing fibrosis F2 by elastography

Investigators had said that correcting more than 50 percent of alleles could cut lung and liver risk by shifting a homozygous organ toward a heterozygous mix. The 35 mg biopsy sits just over that line. A clean A-to-G rewrite at this codon also leaves little work for a prime editor, because the wanted change is a single base and the bystander scan was quiet.

Seven German Patients Received the Infusion in Shanghai

Hannover Medical School says a team from its gastroenterology and pneumology departments, working with Renji Hospital, has now treated seven patients to Shanghai with this editor. The school estimates the deficiency affects about 120,000 people in Europe and is uncommon in Asia, so the German patients had to travel. A Chinese company that holds the patents, and that had refined the method, paid the costs.

That company is YolTech Therapeutics, founded in 2021 in Shanghai. YOLT-202 is its in vivo adenine base editor for the PiZ mutation. The U.S. Food and Drug Administration has granted the program RMAT and Orphan Drug designations. The open-label study at Renji, backed by the Sino-German Center for Cell and Gene Therapy, is testing single infusions at 35 mg, 45 mg, and 55 mg.

YolTech has already said that both the 35 mg and 45 mg doses pushed serum AAT above 11 μM, and that the 45 mg group reached the normal range above 20 μM, with corrected M-AAT above 95 percent. Simon Krooss presented updated figures at the European Respiratory Society Congress in Barcelona on 7 September 2026, including the 35 mg biopsy with up to 57 percent genetic correction and more than six months of AAT above the protective line.

Beam Therapeutics is running a separate liver-targeted base editor, BEAM-302, for the same PiZ mutation in a Western Phase 1/2 trial that reports circulating AAT rather than a published biopsy. The Hannover paper is not the first time anyone has dosed an AATD base editor. It is the first time a journal has printed DNA reads from an edited human liver.

THE SHANGHAI TIMELINE

  1. 18 June 2025: The YOLT-202 investigator-initiated study (NCT07193615) starts at Renji Hospital.
  2. February 2026: YolTech reports the first two PiZZ patients, one at 35 mg and one at 45 mg, both above 11 μM.
  3. March 2026: Katrin H., 55, flies from Hannover to Shanghai with Prof. Michael Ott for a four-week stay and a single infusion.
  4. 7 September 2026: Krooss presents the biopsy and durable AAT data at the ERS Congress in Barcelona.
  5. 1 November 2026: The Journal of Hepatology publishes the 66-year-old man’s 10-week biopsy.
  6. Early 2027: Hannover Medical School plans to resume the clinical trial on its own campus.

Katrin H. Stopped Her Weekly Infusions

Katrin H. is not the man in the paper. She is one of the seven. Shortness of breath had already ended her work as an anesthesiologist; the school diagnosed AATD in 2011, and she had been on weekly plasma-derived AAT, known as augmentation, ever since. “The treatment didn’t help much; the disease has continued to progress slowly and relentlessly,” she said. In March 2026 she spent four weeks in Shanghai, received the infusion, and later showed functional AAT in blood tests. She has not needed augmentation since. “For me, this is like winning the lottery,” she said. Side effects, in her account: none.

The editor cannot unwind emphysema or fibrosis that is already there. She can hope the decline stops. She still works in hospital hygiene in Hannover.

How a Single Base Change Reaches Both Organs

Alpha-1 antitrypsin is made in liver cells and then rides the blood to the lungs, where it shields tissue from the body’s own elastase. In PiZZ disease the Z protein misfolds. Some of it piles up in the liver. Too little of the working form reaches the lung. That is why one gene produces two organ problems, and why a liver-directed edit can, in principle, serve both.

Most gene therapies add a spare copy of a gene, often with a viral vector. This trial does the opposite. It tries to rewrite the broken letter. After the adenine base editor changes the mutated base, a nick on the opposite strand prompts the cell’s own repair to put in the matching partner, so the Z codon becomes the normal glutamate codon without a double-strand cut. YOLT-202 is given once, into a vein, on a non-viral platform.

Michael Ott, senior physician in Hannover’s gastroenterology department and head of its Laboratory for Cell and Gene Therapy, has spent years testing that sequence in animals. The Shanghai collaboration is what moved it into people. “Like most congenital genetic disorders, alpha-1 antitrypsin deficiency is caused by a single tiny building block in the DNA, a so-called base, being incorrectly incorporated,” Ott said.

A Three-Genotype Mosaic Inside One Liver

The press case does not claim a fully corrected organ. It claims a mosaic: some cells PiMM (both copies fixed), some PiMZ (one copy fixed), some still PiZZ. That mix is the product. Investigators argue that a heterozygous state is usually not tied to severe disease, and that crossing 50 percent corrected alleles is the practical goal.

Population genetics is less tidy than that sentence. People who carry one Z copy are not PiZZ, and they are not risk-free either. A 26-study meta-analysis of 27,933 heterozygotes found roughly doubled odds of fibrosis and cirrhosis against MM controls, with a similar lift in liver transplant. Absolute risk stays much lower than in PiZZ, where lifetime cirrhosis figures in the paper’s own introduction run from 20 to 40 percent, but alcohol, fat-liver disease, and extra weight can still turn a leftover Z copy into a problem. The mosaic is a large step down from two Z copies. It is not a silent liver.

WHAT THE MOSAIC ACTUALLY CONTAINS

  • PiMM cells: Both SERPINA1 copies read as the normal M sequence and can make fully folded AAT.
  • PiMZ cells: One copy is still Z, so some misfolded protein can remain even as circulating AAT rises.
  • Unedited PiZZ cells: Both copies stay mutant; those hepatocytes can still store Z polymer.
  • The 50 percent line: The 35 mg biopsy cleared it on both assays, which is why the authors call the lowest dose encouraging.
  • Residual Z risk: Heterozygous livers still show about twice the odds of fibrosis and cirrhosis in pooled studies, especially when other liver insults are present.

Sparse AAT polymer deposits, mild portal inflammation, and mild fibrosis were still visible on the 10-week slide. Without a biopsy from before the infusion, nobody can say those findings improved. They can only say they did not look alarming after the edit.

What the 10-Week Biopsy Still Cannot Prove

A single slide from one man at one dose is a genomic safety document. It is not a liver-outcome trial. It does not show that fibrosis reversed, that emphysema slowed, or that a second patient at 35 mg would match 54 percent. Monthly blood tests found durable, working AAT in this case; they do not replace years of lung function and liver stiffness follow-up.

WHAT WE KNOW

  • On-target edit: 54 percent of alleles by Sanger and 57 percent by Illumina at 10 weeks after 35 mg.
  • Quiet off-target scan: No bystander at the target and no signal at the candidate off-target sites tested.
  • Working protein: Serum AAT 0.70 g/L at 10 weeks, above 0.57 g/L, with elastase blockade intact.
  • Seven treated: Hannover says seven patients received the editor in Shanghai; one biopsy is in print.

WHAT IS UNCONFIRMED

  • Liver improvement: No pre-treatment histology, so polymer and fibrosis cannot be scored as better or worse.
  • Long-term organ protection: Existing lung and liver damage is not reversed; halt of decline is a hope, not a measured endpoint here.
  • Dose pick: 45 mg already reached the normal AAT range above 20 μM in YolTech’s account; whether 35 mg is enough for a registration path is open.
  • Authorization: The product is not approved. Hannover expects to continue the trial on site in early 2027.

Krooss called the efficiency and precision at such a low dose “truly surprising.” Heiner Wedemeyer, chair of gastroenterology at Hannover Medical School and a co-author, said the same method could be aimed at other inherited liver diseases, including coagulation disorders, and at rare “n=1” variants. Those uses need their own biopsies. This paper is the template, not the catalog.

Early 2027 Brings the Trial Back to Hannover

Flights to Shanghai are meant to be a phase, not a permanent care path. Hannover says the clinical trial is scheduled to resume there in early 2027. Until then, European PiZZ patients who want this editor still go to Renji. Augmentation remains the licensed lung treatment: a weekly intravenous protein replacement that does nothing to clear Z polymer from the liver. Transplant is still the only definitive treatment for the liver disease the Z protein causes.

This is a transformative moment. We are now a step closer to offering permanent, minimally invasive therapies to many patients with hereditary liver diseases.

Prof. Dr. Michael Ott, Laboratory for Cell and Gene Therapy, Hannover Medical School

Minimally invasive, in this program, still meant a liver biopsy to prove the genome looked clean, and a four-week stay in Shanghai for the German cohort. Katrin H. is back at her office job. The 66-year-old man’s slide is in a journal with a 2025 impact factor of 40. The next patients will be dosed closer to home, if the 2027 restart holds, with the same bet: that a mosaic just over 50 percent corrected alleles is enough to live with.

Disclaimer: This article is news reporting on a published case and an ongoing early-phase trial. It is informational only and is not medical advice, a treatment recommendation, or a judgment on whether any patient should join a study, stop augmentation, or seek gene editing. Readers should consult a qualified hepatologist, pulmonologist, or clinical geneticist who knows their genotype and organ status before making care decisions. Figures, trial status, and regulatory designations reflect the named sources as of the dates given in the piece and may change as more patients are dosed and followed.

Harry is the editor of COVER 365, an independent publication he owns and runs, and a journalist of ten years who moved from reporting into editing. Anything the site reviews has been used before it is judged. A phone, a car, a game or a piece of travel gear is tested in ordinary conditions, its measured results are set against the maker's specification sheet, and where the two disagree the article says which one to trust and why. No product gets a verdict Harry has not earned by using it. Off the test bench, the same rule of primary evidence applies: business stories come from filings and results, science from the published paper, sports from the governing body's records, and news from statements and transcripts rather than second hand accounts. Coverage runs across technology, auto, gaming, lifestyle and travel as well as news, business, science, sports and entertainment, for readers in every part of the world. Every figure is checked before publication and corrected publicly under a stated policy when wrong. Reader mail is answered at support@cover365.in.

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending